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SUMMARY
Background: The aim of this report was to evaluate the prognostic value and clinical correlations of p53 expres-
sion in children with Wilms’ tumor.
Material and methods: The study comprised 61 children aged from 2 days to 13 years (median 39 months), dia-
gnosed and treated according to SIOP and PPGGL criteria in three centers co-operating with the PPGGL. The
studies were conducted on tumor tissue removed during surgery, fixed in formalin and embedded in paraffin
blocks. Then 4-micron sections were evaluated by immunohistochemistry, using the peroxidase method to de-
termine the expression of p53 in Wilms’ tumor cells by means of primary monoclonal antibody NCL-p53 from
Novocastra.
Results: The percentage of immunopositive cells in particular fragments of the tumor ranged from 0% to 70%
(mean 20.4%, median 16.0%). The mean and median values enabled the children to be divided into two gro-
ups: Group A, where the percentage of cells staining with anti-p53 antibody was >20% (23 cases), and Group
B, where this percentage did not exceed 20%. The expression of p53 was then evaluated in various stages of ad-
vancement and various histological types, depending on the course of the disease. In Group A, tumors at higher
stages of advancement stages were more frequent (p<0.05), and showed a higher degree of malignancy
(p<0.06; EFS=56.53%). In Group B, lower stages of advancement were more frequent (p<0.05), the degree
of malignancy was lower, and the EFS was 81.58%. A discrimination test, however, showed that the determina-
tion of p53 expression in Wilms’ tumor cells has moderate sensitivity (58.825%), positive prediction (43.47%),
and relatively high specificity (70.45%) and negative prediction (81.57%), which means that low indexes of p53
expression have higher prognostic value.
Conclusions: The index of p53 expression is not an independent prognostic factor in Wilms’ tumor in children,
but this determination may be helpful in identifying high-risk and low-risk patients.
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BACKGROUND
Mutations or deletion of suppressor gene p53 are
the most common genetic abnormalities occurring
during cancerogenesis in the majority of neoplasms
in humans. Gene p53, localized on the short arm of
chromosome 17 (17p13), encodes nucleic 53-kDa
phosphoprotein, which affects many functions in
the cell, such as the induction of many genes, the
regulation of the cellular cycle, and apoptosis con-
trol [1,2]. Mutated protein p53 binds to other pro-
teins, and the heterodimer thus created enhances
neoplasmatic transformation in various cells. In ad-
dition, abnormal protein created as a result of the
mutation of one of the p53 alleles can bind to nor-
mal protein produced by the unchanged allele, in-
activating it. Mutated forms of p53 can also act as
oncogenes, especially since their half-life is much
longer than that of other proteins [3,4].
Genome defects in the 17p13 area in neoplasms in
children have been described in lymphoblastic leu-
kemia, soft tissue sarcomas (rhabdomyosarcoma),
osteosarcoma, and Wilms’ tumor, but their role in
Wilms’ tumor has not been fully explained [5,6].
Bardessy et al. [5] found mutations of p53 in 8 ca-
ses among the 140 Wilms’ tumors they studied
(mainly in anaplastic tumors). However, Waber et
al. [7] found no mutations in a group of 44 Wilms’
tumors. Similar results were obtained by Kusafuka
[6] in a group of 13 cases of Wilms’ tumors. Accor-
ding to Velasco et al. [8], the rare occurrence of
p53 mutations in Wilms’ tumors shows that they
are much more complex than mutations occurring
in the hot places commonly seen in neoplasms in
adults. Other studies, however, have shown that
the lack of p53 mutation, as well as over-expression
of p53, are connected with the anaplastic structure
of the tumor and frequent treatment failures [9–11].
The goal of our research was to evaluate the occur-
rence of p53 over-expression in Wilms’ tumor in
children treated according to the recommendations
of the PPGGL (Polish Pediatric Group for the Treat-
ment of Solid Tumors) and the SIOP (International
Society of Pediatric Oncology), and to evaluate the
prognostic value of this over-expression.
MATERIAL AND METHODS
The study involved 61 children (29 girls and 32
boys), from 2 days to 13 years of age (median 39
months), treated for unilateral Wilms’ tumor at
three centers:
• the Surgery and Pediatric Oncology Clinic in the
Institute of Pediatrics at the Medical University of
Lodz (1985–1996);
• the Clinic of Pediatric Surgery in the Polish-Ame-
rican Institute of Pediatrics, Collegium Medicum,
Jagiellonian University (Cracow);
• the Clinic of Pediatric Hematology and Oncolo-
gy, Institute of Pediatrics, Medical University of
Poznaƒ (1993–1996)
All the children included in the study were diagno-
sed and treated according to the criteria recom-
mended by the SIOP (International Society of Pe-
diatric Oncology) and adopted by the Committee
for Wilms’ Tumor in the Polish Pediatric Group for
the Treatment of Solid Tumors (PPGGL). The rese-
arch group is characterized in Table 1.
The tissue samples for examination were taken from
kidney tumors removed directly after diagnosis from
nine children aged below 6 months, and from kid-
ney tumors removed after initial chemotherapy from
52 children aged over 6 months.
The study was conducted on tumor tissue removed
during surgery and fixed in 10% buffered formalin.
The expression of p53 protein in Wilms’ tumor
cells was evaluated in 4-micron sections on adhesi-
ve plates, by the avidin-biotin-peroxidase method,
with monoclonal antibody NCL-p53 DO7 from
Novocastra. High temperature was used to reveal
the antibody against protein p53, i.e. heating for 5
min in a microwave oven, a process which was re-
peated three times. The number of cells staining
with anti-p53 antibody was calculated by ocular
micrometer (type 10/20, PZO Warszawa, Poland).
In all cases the percentage of cells showing p53
expression among all cells was calculated. At least
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Number of cases
Sex
female
male
Age
0-6 months
7-24 months
> 24 months
Stage of advancement
I
II N-
II N+&III
IV
Histological type (degree of malignancy)
low
intermediate
high
necrosis
Local recurrences, metastases
Deaths
Follow up
29
32
6
4
51
26
13
18
3
9
38
11
3
17
10
14–139 months
(median 42 months)
Table 1. Study group characteristics (n = 61).
1000 cells were evaluated in each section, using
a magnification of 400x [12,13].
Statistical analysis
The results we obtained were analyzed statistically
using the chi-squared test, in order to compare the
stage of advancement, histological type and frequ-
ency of recurrences, metastases, and deaths in
Groups A and B and discrimination analysis, in or-
der to determine if the expression of p53 could be
an independent prognostic factor.
RESULTS
A positive immunoreaction was seen in 61 of stu-
died Wilms’ tumors. The percentage of cells sta-
ining with anti-p53 antibody in all three compo-
nents of the tumor ranged from 0% to 70% (mean
20.3%, median 16%). The expression of p53 was
highest in the epithelial elements of Wilms’ tumors
(70%) and in the blastema (68%), the lowest in the
stroma (35%) (Table 2).
According to pathologists’ recommendations [12,
13], the mean values enabled the subject children to
be divided into two groups: Group A, where the
percentage of cells staining with anti-p53 antibody
was >20% (23 cases = 37.7%), and Group B, whe-
re this percentage did not exceed 20% (38 cases =
62.3%). In both groups, we studied the dependence
between the percentage of cells staining with anti-
-p53 antibody on the one hand, and the stage of ad-
vancement, histological type of the tumor, and fre-
quency of treatment failure on the other.
Expression of p53 and stage of advancement
The percentage of cells with p53 expression in parti-
cular stage of advancement is presented in Table 3.
In Group A (n = 23), six children (26%) were in CS
I, six (26%) in CS IIN-; ten (43.3%) in CS IIN+&III,
and one case in CS IV. In Group B (n = 38) 20 chil-
dren were in CS I (52.6%), 7 in CS IIN- (18.4%), 8 in
CS IIN+&III (43.4%), and 3 in CS IV. Statistical ana-
lysis revealed more frequent p53 expression >20%
in the tumors removed from patients in CS II N+&III
in group A than in group B, and more frequent p53
expression < 20% in tumors removed from patients
in CS I in Group B than in Group A, at a significance
level of p < 0.05 (Table 3).
Expression of p53 and the histological tumor type
The percentage of cells with p53 expression in par-
ticular histological types of Wilms’ tumor is presen-
ted in Table 4. In Group A (n = 23), a low degree
of malignancy (‘favorable outcome’ according to
the older histological classification scheme) was dia-
gnosed by the pathologist in one case (4.3%); an in-
termediate degree of malignancy (‘standard outco-
me’ in the former histological classification) in 14
cases (60%); a high degree of malignancy (‘poor
outcome’ in the former histological classification) in
7 cases (30%), and necrosis, which made classifica-
tion difficult, in one case. In Group B (n = 38)
a low degree of malignancy was diagnosed in 8 ca-
ses (21%), an intermediate degree of malignancy in
24 cases (63%), a high degree of malignancy in 4
cases (10%), and necrosis making classification diffi-
cult in 2 cases. Although a low degree of malignan-
cy was diagnosed in Group A several times more ra-
rely, and a high degree of malignancy three times
more frequently than in Group B, the chi-squared
test did not reveal the difference to be statistically
significant (p=0.06).
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Stage of clinical
advancement
Total
> 20% < 20%
I n = 26
IIN- n = 13
IIN+&III n= 18
IV n = 4
26%
26%
43.5%
1*
52.6%
18.4%
21%
3*
Table 3. Expression p53: the percentage of immunopositive cells in
particular stages of advancement of Wilms’ tumour.
Histological type/
degree of malignancy
Total
> 20% < 20%
Low n = 9
Intermediate n = 38
High n = 11
necrosis n = 3
4.3%
60%
30%
1*
21%
63%
10%
2*
Table 4. Expression of p53: the percentage of immunopositive cells in
particular histological types of Wilms’ tumour.
p53 expression Epithelium % Blastema % Stroma %
Minimum
Maximum
Mean
Standard deviation
Median
0.000
70.000
14.656
16.620
11.000
0.000
68.000
8.656
14.690
0.000
0.000
35.000
0.565
4.445
0.000
Table 2. p53: the percentage of immunopositive cells in particular
components of Wilms’ tumor.
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Expression of p53 and frequency of recurrences,
metastases and deaths
Among the 38 children in whom the percentage of
cells staining with anti-p53 antibody was less than
20%, failure of treatment was seen in 7 cases
(18.42%). Among 7 children with treatment failure,
1 died (a 5-year-old girl with focal anaplasia in Sta-
ge II, 35 months after nephrectomy), 3 children are
still under treatment for recurrence, and 3 children
are in second remission. However, among the 23
children in whom the percentage of cells staining
with anti-p53 antibody among tumor cells was
greater than 20%, treatment failure was seen in 10
children (43.47%), of whom 9 died due to disease
progression, and 1 is still under treatment for a pul-
monary recurrence. The results of this study show
that treatment failure is significantly more frequent
in tumors where the percentage of cells staining
with anti-p53 antibody is 20% or more, at the level
of p<0.05 (Table 3).
In order to evaluate the clinical value of testing to
determine p53 expression, a discrimination test
was done. Our analysis showed:
• indirect sensitivity, i.e. the probable percentage
of truly positive over-expression of p53 (>20%)
in the group of children with treatment failure
(58.82);
• relatively high specificity, i.e. the probable per-
centage of truly low expression of p53 (<20%) in
the group of children with incident-free survival
(70.45);
• prediction (+), i.e. the probable percentage of
treatment failure in children in whom tumor cells
show over-expression of p53 >20% (43.47);
• high prediction (-), i.e. the probable percentage
of incident-free survival in children in whom tu-
mor cells showed a low percentage of cells sta-
ining with p53 antibody (<20%) (81.57).
The statistical analysis we conducted demonstrates
that the determination of p53 over-expression is
a useful prognostic test.
DISCUSSION
Wilms’ tumor develops in the kidneys from small
primary persistent focuses of blastema, the so-cal-
led nephrogenic rests, which undergo neoplasma-
tic transformation due to the inactivation of various
genes [14]. Cytogenetic and molecular studies con-
ducted in numerous American and European cen-
ters have shown that susceptibility to Wilms’ tumor
is a complex phenomenon, involving more than
one genetic locus and interactions between genetic
and epigenetic factors. Although the Wilms’ tumor
suppressor gene (WT1) mapped in chromosome
11p13 is the best-known anti-oncogene associated
with Wilms’ tumor, p53 mutations have occasio-
nally been implicated in the pathogenesis of
Wilms’ tumor [7,8,11,15].
This study is based on the immunohistochemica-
l detection of p53 protein, which generally can be
assumed to indicate a genetic alteration in the p53
tumor suppressor gene. Nevertheless, the results of
immunohistochemical studies for the presence of
p53 protein should be interpreted very carefully.
The proper interpretation of p53 protein immuno-
positivity still remains an unresolved question, even
though most researchers now believe that the pre-
sence of staining in the majority of cells is associa-
ted with mutation and influences the clinical out-
come. The cut-off for what constitutes the ‘majori-
ty’, hence positive staining, nonetheless remains
unclear. The value accepted in various studies has
ranged widely, from >10% to >75% of the tumor
cells. In our work the value of the mean was set at
20%, due to the fact that pathologists suggest using
mean and median values of the results obtained in
order to assess the prognostic value of the proteins
involved in the cellular cycle [12,13].
The studies we conducted revealed that positive
immunoreaction is most frequent in epithelial cells
and in blastema, and much less frequent in the
stroma. This observation is consistent with that of
Cheah et al. [9], who also noted positive reactions
more frequently in blastemal cells. This observation
confirms the common belief that blastema-type tu-
mors have a worse prognosis.
We observed that a higher stage of advancement
correlates with an increasing percentage of tumors
in which cells staining with anti-p53 antibody con-
stitute 20% or more, and with a decrease in the
number of tumors in which the percentage of cells
staining with anti-p53 antibody is <20%. Statistical
analysis showed that an increased stage of advan-
cement of Wilms’ tumor significantly increases the
number of tumors with 20% or more of cells sta-
ining with anti-p53 antibody. No significant corre-
lation was seen between the stage of advancement
and the intensity of immunopositive p53 reaction
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in any of the 3 components of the tumor. The de-
pendence between the stage of advancement and
percentage of cells staining with anti-p53 antibody
seen in our study seems to result from the incre-
ased aggressiveness of neoplastic cells in the higher
stages of advancement, due to the loss of p53
function and the increase in replication potential
[1]. We did not compare our results with those ob-
tained by other researchers, as there are no reports
on this topic in the literature.
As for rhe expression of p53 and the histological ty-
pe of tumor: in the majority of tumors with a low
(88.50%) or intermediate degree of malignancy
(63.16%) (formerly described as favorable and
standard), the percentage of cells staining with an-
ti-p53 antibody was <20% in all three components
of the tumor. A low percentage of cells staining
with anti-p53 antibody was also seen in 1/3 of the
tumors with a high grade of malignancy (formerly
‘unfavorable’). These differences were not seen in
particular elements of tumors. A high percentage of
cells staining with anti-p53 antibody (>20%) was
seen in all 4 tumors with diffuse anaplasia, in 2 out
of 5 with focal anaplasia, and in 1 out of 2 tumors
with sarcomatic stroma. These observations are
consistent with those of other authors, who have
noted over-expression of p53 mainly in anaplastic
tumors [5,6,9,10]. The high percentage of cells sta-
ining with anti-p53 antibody (>20%) in high mali-
gnancy tumors (mainly those with diffuse anapla-
sia) is probably connected with the appearance of
cells which have lost the p53 function and become
aneuploid with various chromosomal transforma-
tions. It has been suggested that a high level of
aneuploidia is responsible for resistance to chemo-
therapy and poor prognosis [14–16]. It is thought
that diffuse anaplasia – diffuse dissemination of
anaplastic cells – is connected with a poor progno-
sis, and focal anaplasia in Wilms’ tumors without
extra renal diffusion (stage I) with good prognosis
[16–18]. Although it has been noted that an incre-
ase in the malignancy of Wilms’ tumor is connec-
ted with an increase in the percentage of immuno-
positive cells, this observation has not been confir-
med statistically. It may be dependent on the num-
ber of cases in the research groups. It has been
suggested that the amount of p53 expression by
Wilms’ tumors may be linked to tumor aggressive-
ness associated with anaplasia [5,10,16]. A specu-
lative explanation may be that these more sinister
tumors with unfavorable histology show more ra-
pid and active production or slower elimination of
mutant protein. This may in turn result in increased
inhibition of oncogenic suppression or heightened
oncogenic activity, as suggested by increased ag-
gressiveness.
The analysis of the disease course in children with
Wilms’ tumor shows significantly more frequent
occurrence (p<0.005) of relapses, metastases, and
death in children in whom the tumors cells show
an over-expression of p53>20. Treatment failures
mainly involved children with Wilms’ tumors the in
high and intermediate degree of malignancy at the
stage of advancement CS IIN+&III. Our observa-
tions are consistent with those of other authors
[5,6,9–11], who have observed over-expression of
p53 in anaplastic Wilms’ tumors. The presence of
p53 over-expression also in anaplastic tumors re-
moved after initial chemotherapy suggests that the-
se tumors are resistant to currently used treatment
methods. It should be noted that there were no fa-
ilures of treatment in children with Wilms’ tumor
in the low or intermediate degree of malignancy
and in Stage I of advancement, where the expres-
sion of p53 was <20%. This may suggest a favora-
ble prognosis for this group.
The discrimination analysis revealed that although
over-expression of p53 is connected with a higher
stage of advancement and significantly more frequ-
ent treatment failures, it is not an independent pro-
gnostic factor. This is demonstrated by the low sen-
sitivity (58.82%) and low positive prediction
(43.47%) of this determination. However, the rela-
tively high specificity (70.45%) and negative pre-
diction (81.57%) may suggest that a low percenta-
ge of immunopositive cells may help to classify
a child in the low risk group.
CONCLUSIONS
The index of p53 expression is not an independent
prognostic factor in Wilms’ tumor in children, but
it may be helpful in the identification of high risk
and low risk patients.
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